Cipla wins $189 mn contract from Global Fund ARV

P T Jyothi Datta Mumbai | Updated on January 24, 2018

Drugmaker Cipla has been awarded a contract by the Global Fund ARV Tender to supply anti-AIDS medicines worth $ 188.95 million.

This means that the Mumbai-based drugmaker has been selected as a ‘panel supplier’ for a supplier partnership agreement. The contract is effective January 1, 2015 and will run for a period of three years, Cipla said.

And the supplies will begin from the fourth quarter of the financial year 2015, it added.

Subhanu Saxena, Cipla’s Managing Director and Global Chief Executive, said in a statement: “We are extremely proud to have won this tender from Global Fund. Cipla has been committed to the cause of HIV/AIDS for over two decades and this tender offers us a great opportunity to make HIV/AIDS treatment accessible to more than 140 countries through Global Fund.”

Cipla has a long-term association with Global Fund since 2002. And last year, Cipla was one of the suppliers awarded with a long-term contract for supplying anti-malarial drugs.

The anti-retrovirals (ARV) drugs will be manufactured at Cipla’s manufacturing facilities in India, which has been approved by various international regulatory agencies, it said.

Published on February 13, 2015

Follow us on Telegram, Facebook, Twitter, Instagram, YouTube and Linkedin. You can also download our Android App or IOS App.

This article is closed for comments.
Please Email the Editor